Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis

Abstract Background Hepatocellular carcinoma (HCC) is a common primary malignant tumor which usually progresses to an advanced stage because of late diagnosis. Sorafenib (Sora) is a first line medicine for advanced stage HCC; however, it has been faced with enormous resistance. Simvastatin (Sim) is...

Full description

Bibliographic Details
Main Authors: Jiao Feng, Weiqi Dai, Yuqing Mao, Liwei Wu, Jingjing Li, Kan Chen, Qiang Yu, Rui Kong, Sainan Li, Jie Zhang, Jie Ji, Jianye Wu, Wenhui Mo, Xuanfu Xu, Chuanyong Guo
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Sorafenib resistance
Simvastatin
Glycolysis
Hepatocellular carcinoma
PKM2
HIF-1α
Online Access:https://doi.org/10.1186/s13046-020-1528-x

Internet

https://doi.org/10.1186/s13046-020-1528-x

Similar Items